首页> 美国卫生研究院文献>British Journal of Cancer >Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

【2h】

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

机译：卡波替尼与依维莫司在晚期肾细胞癌的3期METEOR试验中基于先前治疗的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy.

机译：背景技术在3期METEOR试验中，经过抗血管生成治疗后，卡博替尼与依维莫司相比可改善依维莫司的无进展生存期（PFS），客观缓解率（ORR）和总体生存期（OS）。

著录项

期刊名称 British Journal of Cancer
作者
Thomas Powles; Robert J. Motzer; Bernard Escudier; Sumanta Pal; Christian Kollmannsberger; Joanna Pikiel; Howard Gurney; Sun Young Rha; Se Hoon Park; Poul F. Geertsen; Marine Gross-Goupil; Enrique Grande; Cristina Suarez; David W. Markby; Alan Arroyo; Mark Dean; Toni K. Choueiri; Daniel George;
展开▼
作者单位

展开▼
年(卷),期 2018(119),6
年度 2018
页码 663–669
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma [J] . Thomas Powles, Robert J. Motzer, Bernard Escudier, British Journal of Cancer . 2018,第6期

机译：卡博替尼与依维莫司在晚期肾细胞癌的3期METEOR试验中基于先前治疗的结果
2. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma [J] . Thomas Powles, Robert J. Motzer, Bernard Escudier, British Journal of Cancer . 2018,第6期

机译：卡博替尼与依维莫司在晚期肾细胞癌的3期METEOR试验中基于先前治疗的结果
3. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2020,第期

机译：基于年龄在高级肾细胞癌患者的Cabozantinib患者的III阶段流星试验的成果
4. Integration of Surgery and Systemic Therapy in the Treatment of Locally Advanced and Metastatic Renal Cell Carcinoma [C] . Christopher G. Wood Genitourinary Cancers Symposium . 2011

机译：外科和全身治疗在局部晚期和转移性肾细胞癌中的整合
5. Tumor Infiltrating Lymphocyte Therapy for Renal Cell Carcinoma: Methods for ex vivo Expansion and T-Cell Memory Induction [D] . Braun, Mitchell W. 2021

机译：肾细胞癌患者肿瘤浸润淋巴细胞治疗：用于脱型膨胀和T细胞记忆诱导的方法
6. Outcomes based on plasma biomarkers in METEOR a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma [O] . Thomas Powles, Toni K. Choueiri, Robert J. Motzer, 2021

机译：基于血浆生物标志物的结果在晚期肾细胞癌中的Cabozantib vs everolimus的随机相3试验
7. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma [O] . Thomas Powles, Robert J. Motzer, Bernard Escudier, 2018

机译：基于先前治疗的成果在Cabozantib的第3期流星试验中，在晚期肾细胞癌中的extiolimus

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅